Assetmark, Inc Fulgent Genetics, Inc. Transaction History

Assetmark, Inc

$32.1 Billion
Q2 2024

A detailed history of Assetmark, Inc transactions in Fulgent Genetics, Inc. stock. As of the latest transaction made, Assetmark, Inc holds 8 shares of FLGT stock, worth $169. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 8 -0.0%

Holding current value

$169

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	SELL	$21.55 - $29.29 $2,736 - $3,719	-127 Reduced 94.07%	8 $0
Q4 2023 Feb 09, 2024	SELL	$23.64 - $30.27 $452,800 - $579,791	-19,154 Reduced 99.3%	135 $3,000
Q3 2023 Oct 27, 2023	SELL	$26.74 - $40.81 $19,974 - $30,485	-747 Reduced 3.73%	19,289 $515,000
Q2 2023 Aug 11, 2023	BUY	$28.52 - $40.7 $44,633 - $63,695	1,565 Added 8.47%	20,036 $741,000
Q1 2023 May 05, 2023	BUY	$29.39 - $36.27 $276,354 - $341,046	9,403 Added 103.69%	18,471 $576,000
Q4 2022 Feb 10, 2023	SELL	$29.23 - $40.28 $194,262 - $267,700	-6,646 Reduced 42.29%	9,068 $270,000
Q3 2022 Nov 01, 2022	BUY	$37.92 - $63.74 $23,320 - $39,200	615 Added 4.07%	15,714 $599,000
Q2 2022 Aug 03, 2022	BUY	$47.98 - $62.75 $69,523 - $90,924	1,449 Added 10.62%	15,099 $823,000
Q1 2022 May 13, 2022	BUY	$49.85 - $96.11 $11,415 - $22,009	229 Added 1.71%	13,650 $852,000
Q4 2021 Feb 14, 2022	BUY	$77.3 - $105.0 $27,905 - $37,905	361 Added 2.76%	13,421 $1.35 Million
Q3 2021 Nov 12, 2021	BUY	$74.87 - $110.87 $973,085 - $1.44 Million	12,997 Added 20630.16%	13,060 $1.18 Million
Q2 2021 Aug 16, 2021	BUY	$66.8 - $100.45 $4,208 - $6,328	63 New	63 $6,000

Others Institutions Holding FLGT

# of Institutions

195

Shares Held

15.3M

Call Options Held

1.07M

Put Options Held

27.9K

View Full List

About Fulgent Genetics, Inc.

Ticker FLGT
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 30,265,800
Market Cap $640M
Description
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions...

More about FLGT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Assetmark, Inc with notifications on news.

Account